|
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. |
|
|
Honoraria - Athenex; bioTheranostics; natera; OncoCyte |
Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Bristol Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Pfizer; Roche/Genentech; Seagen; Syndax |
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
(OPTIONAL) Uncompensated Relationships - Foundation Medicine; NanoString Technologies |
|
|
Stock and Other Ownership Interests - Sividon Diagnostics |
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Merck; Molecular Health; MSD Oncology; Roche |
Research Funding - Myriad Genetics (Inst); Roche (Inst) |
Patents, Royalties, Other Intellectual Property - Patent application WO2020109570A1 - cancer immunotherapy; Patent applications WO2015114146A1 and WO2010076322A1- therapy response; VMScope digital pathology software |
|
|
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda |
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda |
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer |
Research Funding - Seagen (Inst) |
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; GRAIL; Ipsen; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen |
|
|
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar |
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung |
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks |
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst) |
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. |
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche |
|
|
Honoraria - AstraZeneca; Eisai Europe; Lilly; MSD; Pfizer; Roche/Genentech |
Consulting or Advisory Role - AstraZeneca; Eisai; Merck; Novartis; Pfizer; Roche |
Research Funding - AstraZeneca; Roche |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Genomic Health; Immunomedics; Lilly; Merck; Pfizer; Puma Biotechnology; Puma Biotechnology; Seagen |
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); ZIOPHARM Oncology (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; DAVA Pharmaceuticals; Genentech; Immunomedics; Lilly; Lilly; Lilly; Lilly; Merck; Pfizer; Puma Biotechnology; Spectrum Pharmaceuticals |
Other Relationship - Genomic Health; Lilly |
|
|
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Genomic Health; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; pfm medical; Roche/Genentech; Seagen; SOMATEX; Sonoscape |
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche; Sonoscape |
(OPTIONAL) Uncompensated Relationships - West German Study Group |
|
|
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst) |
Other Relationship - UpToDate |
|
|
Honoraria - Merck; Novartis; Pfizer |
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche |
Research Funding - AstraZeneca; Gencurix (Inst); Novartis; Pfizer; Roche (Inst) |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck; Merck Sharp & Dohme; Novartis; Oncosec; Pfizer; Roche; Seagen |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck; Merck Sharp & Dohme; Novartis; Oncosec; Pfizer; Roche; Seagen |
Research Funding - AstraZeneca (Inst); BMSi (Inst); Corvus Pharmaceuticals (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); OncoSec (Inst); Roche (Inst); Seagen (Inst) |
|
|
Stock and Other Ownership Interests - West German Study Group |
Honoraria - Amgen; AstraZeneca; Daiichi-Sankyo; Exact Sciences; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen |
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I) |
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Roche/Genentech (Inst) |
|
|
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Lilly; Pfizer |
Research Funding - Eisai (Inst); Kyowa Hakko Kirin (Inst); Nippon Kayaku (Inst); Taiho Pharmaceutical (Inst) |
|
|
Honoraria - Agendia (Inst); Amgen (Inst); Art Tempi (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai Europe (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst) |
Consulting or Advisory Role - Agendia (Inst); Amgen (Inst); Art Tempi (Inst); AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Molecular Health (Inst); MSD Oncology (Inst); Mylan (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi Aventis GmbH (Inst) |
|
|
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen |
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen |
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline; IQvia; Macrogenics; Medscape; Merck Sharp & Dohme; Merus; Mundipharma; Mylan; Novartis; Pfizer; Pierre Fabre; Prime Oncology; Roche; Samsung Bioepis; Sanofi; Seagen; Teva; touchIME |
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
No Relationships to Disclose |
|
|
|
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche |
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst) |